AR097436A1 - Bis-amidopiridinas - Google Patents
Bis-amidopiridinasInfo
- Publication number
- AR097436A1 AR097436A1 ARP140103171A ARP140103171A AR097436A1 AR 097436 A1 AR097436 A1 AR 097436A1 AR P140103171 A ARP140103171 A AR P140103171A AR P140103171 A ARP140103171 A AR P140103171A AR 097436 A1 AR097436 A1 AR 097436A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- alkyl
- optionally
- groups
- whose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Su uso como miméticos de SMAC, composiciones farmacéuticas que las contienen y su uso como medicamentos para el tratamiento y/o la prevención de enfermedades caracterizadas por proliferación celular excesiva o anormal y condiciones asociadas tales como cáncer. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) en donde, R¹ está seleccionado de -CH₃, -CH₂CH₃, -haloalquilo C₁₋₃ y -H; R² está seleccionado de -H, -alquilo C₁₋₃; R²ᵃ está seleccionado de -H, -alquilo C₁₋₃; R³ está seleccionado de bencilo, fenilo y heteroarilo de 5 - 12 miembros, cada uno de cuyos grupos puede estar sustituido, opcional e independientemente, con uno o varios grupos seleccionados, de modo independiente, de R⁵ o R³ es heterociclilo aromático de 8 - 12 miembros, cada uno de cuyo grupo heterociclilo puede estar sustituido, opcional e independientemente, con uno o varios grupos seleccionados, de modo independiente, de =O y R⁵; R⁴ está seleccionado de -H, halógeno, fenilo, naftilo y heteroarilo de 5 - 12 miembros, cada uno de cuyos grupos puede estar sustituido, opcional e independientemente, con uno o varios grupos seleccionados, de modo independiente, de R⁶ o R⁴ es heterociclilo aromático de 8 - 12 miembros, cuyo heterociclilo puede estar sustituido, opcional e independientemente con uno o varios grupos seleccionados, de modo independiente, de =O y R⁶; R⁵ está seleccionado de halógeno, -CN, -alquilo C₁₋₃, -O-alquilo C₁₋₅; R⁶ está seleccionado de halógeno, -CN, -NH₂, -alquilo C₁₋₃, -haloalquilo C₁₋₃, -O-alquilo C₁₋₃; en donde los compuestos de la fórmula (1) pueden estar opcionalmente presentes en la forma de sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13181578 | 2013-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097436A1 true AR097436A1 (es) | 2016-03-16 |
Family
ID=49003720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103171A AR097436A1 (es) | 2013-08-23 | 2014-08-22 | Bis-amidopiridinas |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9249151B2 (es) |
| EP (1) | EP3036235B1 (es) |
| JP (1) | JP6424224B2 (es) |
| AR (1) | AR097436A1 (es) |
| TW (1) | TW201605827A (es) |
| UY (1) | UY35711A (es) |
| WO (1) | WO2015025018A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| AR101479A1 (es) | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
| MX379967B (es) | 2016-05-19 | 2025-03-11 | Boehringer Ingelheim Int | Procesos para la elaboración de derivados de 6-alquinil-piridina. |
| WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
| US20200046684A1 (en) | 2017-03-31 | 2020-02-13 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| EP3284739A1 (de) | 2017-07-19 | 2018-02-21 | Bayer CropScience Aktiengesellschaft | Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel |
| CN113453678A (zh) | 2018-11-26 | 2021-09-28 | 德彪药业国际股份公司 | Hiv感染的联合治疗 |
| TWI894135B (zh) | 2019-01-25 | 2025-08-21 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
| WO2021026349A1 (en) | 2019-08-08 | 2021-02-11 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Combination therapy for treatment of cancer |
| CN114727984A (zh) | 2019-09-25 | 2022-07-08 | 德彪药业国际股份公司 | 治疗患有局部晚期鳞状细胞癌的患者的给药方案 |
| US20230219961A1 (en) * | 2020-05-12 | 2023-07-13 | Suzhou Alphama Biotechnology Co., Ltd. | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof |
| JP7406008B2 (ja) * | 2020-05-12 | 2023-12-26 | 蘇州阿尓脈生物科技有限公司 | Cdk9阻害剤としての多環式アミド系誘導体、その調製方法及び用途 |
| CR20220606A (es) | 2020-06-03 | 2023-01-23 | Boehringer Ingelheim Int | Rhabdovirus recombinante que codifica una proteína de fusión fc de dominio extracelular cd80 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509721A (pt) * | 2004-04-07 | 2007-09-25 | Novartis Ag | inibidores de iap |
| ATE542798T1 (de) * | 2006-12-07 | 2012-02-15 | Novartis Ag | Organische verbindungen |
| WO2008133192A1 (ja) * | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| DE102007036075A1 (de) * | 2007-08-01 | 2009-02-05 | Bayer Healthcare Ag | Prodrugs und ihre Verwendung |
| US20110117081A1 (en) * | 2008-05-05 | 2011-05-19 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
-
2014
- 2014-08-20 US US14/463,690 patent/US9249151B2/en active Active
- 2014-08-21 JP JP2016535486A patent/JP6424224B2/ja active Active
- 2014-08-21 UY UY35711A patent/UY35711A/es unknown
- 2014-08-21 EP EP14755650.0A patent/EP3036235B1/en active Active
- 2014-08-21 WO PCT/EP2014/067858 patent/WO2015025018A1/en not_active Ceased
- 2014-08-22 AR ARP140103171A patent/AR097436A1/es unknown
- 2014-08-22 TW TW103129096A patent/TW201605827A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201605827A (zh) | 2016-02-16 |
| JP6424224B2 (ja) | 2018-11-14 |
| WO2015025018A1 (en) | 2015-02-26 |
| UY35711A (es) | 2015-02-27 |
| EP3036235A1 (en) | 2016-06-29 |
| JP2016531126A (ja) | 2016-10-06 |
| EP3036235B1 (en) | 2017-04-19 |
| US9249151B2 (en) | 2016-02-02 |
| US20150057286A1 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097436A1 (es) | Bis-amidopiridinas | |
| AR097435A1 (es) | 6-alquinilpiridinas | |
| AR090159A1 (es) | 5-alquinil piridinas | |
| AR098337A1 (es) | Triazolopirazina | |
| AR119454A2 (es) | COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO | |
| AR089776A1 (es) | 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir | |
| CO7131357A2 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
| CO7131358A2 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| AR101479A1 (es) | Derivados de 6-alquinil-piridina | |
| AR100137A1 (es) | Compuestos 4-amino-imidazoquinolina | |
| UY38712A (es) | Lactamas fusionadas de arilo y heteroarilo | |
| UY35639A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR106314A1 (es) | COMPUESTOS DE ESPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53 | |
| CO2018002829A2 (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) | |
| AR090230A1 (es) | Derivados macrociclicos para el tratamiento de enfermedades | |
| ECSP14008606A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| DOP2016000014A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| PE20150966A1 (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina | |
| ECSP16074478A (es) | Compuestos novedosos | |
| CO7160077A2 (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
| UY35653A (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR098492A1 (es) | Derivados de purina | |
| CR20150456A (es) | Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |